Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jun;64(6):751–757. doi: 10.1136/jnnp.64.6.751

Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases

S Jitpimolmard 1, S Tiamkao 1, M Laopaiboon 1
PMCID: PMC2170133  PMID: 9647304

Abstract

OBJECTIVE— To describe the long term efficacy and side effects of the treatment of hemifacial spasm with Dysport and to evaluate two different sites of injection to hopefully reduce side effects.
METHODS—This study was designed as a prospective descriptive study. Injections were made subcutaneously around the eye. Peak improvement was subjectively assessed by using a visual analogue scale and reported in percentages (0-100%). Duration of improvement was assessed subjectively and reported in months.
RESULTS—Of 175 cases, 17 were lost to follow up and were excluded. 855 treatments were injected in the remaining 158 patients with a median of 4 treatments. The response rate was 97%. Of 855 treatments, the adjusted mean peak and duration of improvement was 77.2 (95% confidence interval (95%CI) 74.7-79.4)% and 3.4 (95%CI 3.2-3.6) months respectively. In 158 patients (complete group), the long term results from the first to the 12th treatment showed that the mean peak improvement ranged from 72.70 to 80.10% and the duration of improvement was 2.60 to 3.71 months. It remained constant throughout (p=0.40, p=0.87 respectively). The most common side effect was ptosis. Of the 158 patients, 21 completed 12 treatments (subgroup). A separate analysis of this group disclosed a mean peak and duration of improvement from the first to 12th treatments ranging from 70.00 to 78.10% and 2.65 to 4.31 months respectively. Analysis of variance with repeated measures showed no significant variation of peak and duration of improvement over the first to the 12th treatments (p=0.38, p=0.38 respectively). Only 3% of the treatments were unsuccessful but responded to subsequent treatments. The incidence of ptosis was reduced from 27.17% to 9.68% by moving the injection site to the lateral part of orbital orbicularis oculi without any loss of efficacy. The yearly cost of Dysport is considerably less than Botox.
CONCLUSION—This study is the first to show, in detail, the long term results of treatments of hemifacial spasm with Dysport. The efficacy is constant throughout the first to 12th treatments in both the complete group and subgroup. Ptosis can be reduced by moving the injection site further up to the lateral part of the orbital orbicularis oculi. The efficacy of Dysport is comparable with Botox® in long term follow up.



Full Text

The Full Text of this article is available as a PDF (138.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aramideh M., Ongerboer de Visser B. W., Brans J. W., Koelman J. H., Speelman J. D. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):309–311. doi: 10.1136/jnnp.59.3.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barker F. G., 2nd, Jannetta P. J., Bissonette D. J., Shields P. T., Larkins M. V., Jho H. D. Microvascular decompression for hemifacial spasm. J Neurosurg. 1995 Feb;82(2):201–210. doi: 10.3171/jns.1995.82.2.0201. [DOI] [PubMed] [Google Scholar]
  3. Carruthers J., Carruthers A., Bagaric D. Can ptosis incidence be reduced after lid injections of botulinum A exotoxin for blepharospasm and hemifacial spasm? Can J Ophthalmol. 1995 Apr;30(3):147–147. [PubMed] [Google Scholar]
  4. Chong P. N., Ong B., Chan R. Botulinum toxin in the treatment of facial dyskinesias. Ann Acad Med Singapore. 1991 Mar;20(2):223–227. [PubMed] [Google Scholar]
  5. Digre K., Corbett J. J. Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol. 1988;49:151–176. [PubMed] [Google Scholar]
  6. Dutton J. J., Buckley E. G. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988 Nov;95(11):1529–1534. doi: 10.1016/s0161-6420(88)32977-5. [DOI] [PubMed] [Google Scholar]
  7. Elston J. S. Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry. 1986 Jul;49(7):827–829. doi: 10.1136/jnnp.49.7.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Elston J. S. The management of blepharospasm and hemifacial spasm. J Neurol. 1992 Jan;239(1):5–8. doi: 10.1007/BF00839203. [DOI] [PubMed] [Google Scholar]
  9. Flanders M., Chin D., Boghen D. Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol. 1993;33(4):316–319. doi: 10.1159/000116961. [DOI] [PubMed] [Google Scholar]
  10. Frueh B. R., Felt D. P., Wojno T. H., Musch D. C. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol. 1984 Oct;102(10):1464–1468. doi: 10.1001/archopht.1984.01040031184014. [DOI] [PubMed] [Google Scholar]
  11. Frueh B. R., Musch D. C. Treatment of facial spasm with botulinum toxin. An interim report. Ophthalmology. 1986 Jul;93(7):917–923. doi: 10.1016/s0161-6420(86)33641-8. [DOI] [PubMed] [Google Scholar]
  12. Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry. 1996 Jun;60(6):704–704. doi: 10.1136/jnnp.60.6.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jankovic J., Schwartz K., Donovan D. T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):633–639. doi: 10.1136/jnnp.53.8.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kraft S. P., Lang A. E. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Can J Neurol Sci. 1988 Aug;15(3):276–280. doi: 10.1017/s0317167100027748. [DOI] [PubMed] [Google Scholar]
  15. Loeser J. D., Chen J. Hemifacial spasm: treatment by microsurgical facial nerve decompression. Neurosurgery. 1983 Aug;13(2):141–146. doi: 10.1227/00006123-198308000-00006. [DOI] [PubMed] [Google Scholar]
  16. Piatt J. H., Jr, Wilkins R. H. Treatment of tic douloureux and hemifacial spasm by posterior fossa exploration: therapeutic implications of various neurovascular relationships. Neurosurgery. 1984 Apr;14(4):462–471. doi: 10.1227/00006123-198404000-00012. [DOI] [PubMed] [Google Scholar]
  17. Poungvarin N., Devahastin V., Viriyavejakul A. Treatment of various movement disorders with botulinum A toxin injection: an experience of 900 patients. J Med Assoc Thai. 1995 Jun;78(6):281–288. [PubMed] [Google Scholar]
  18. Poungvarin N., Viriyavejakul A. Two hundred and fifty patients with hemifacial spasm treated with botulinum toxin injection. J Med Assoc Thai. 1992 Apr;75(4):199–203. [PubMed] [Google Scholar]
  19. Price J., O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol. 1994 Nov;22(4):255–260. doi: 10.1111/j.1442-9071.1994.tb00793.x. [DOI] [PubMed] [Google Scholar]
  20. Shaari C. M., Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993 Sep;16(9):964–969. doi: 10.1002/mus.880160913. [DOI] [PubMed] [Google Scholar]
  21. Simpson L. L. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol. 1986;26:427–453. doi: 10.1146/annurev.pa.26.040186.002235. [DOI] [PubMed] [Google Scholar]
  22. Taylor J. D., Kraft S. P., Kazdan M. S., Flanders M., Cadera W., Orton R. B. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol. 1991 Apr;26(3):133–138. [PubMed] [Google Scholar]
  23. Tsoy E. A., Buckley E. G., Dutton J. J. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol. 1985 Feb 15;99(2):176–179. doi: 10.1016/0002-9394(85)90228-4. [DOI] [PubMed] [Google Scholar]
  24. Van den Bergh P., Francart J., Mourin S., Kollmann P., Laterre E. C. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 1995 Jul;18(7):720–729. doi: 10.1002/mus.880180708. [DOI] [PubMed] [Google Scholar]
  25. Yu Y. L., Fong K. Y., Chang C. M. Treatment of idiopathic hemifacial spasm with botulinum toxin. Acta Neurol Scand. 1992 Jan;85(1):55–57. doi: 10.1111/j.1600-0404.1992.tb03995.x. [DOI] [PubMed] [Google Scholar]
  26. Zeger S. L., Liang K. Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986 Mar;42(1):121–130. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES